⚠️
Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Elevated cost per beneficiary
Risk indicators are statistical patterns, not allegations. Learn more
8,703
Total Claims
$6.5M
Drug Cost
1,096
Beneficiaries
$5,926
Cost/Patient
Risk Score Breakdown 3/100
Low (0)Moderate (15)Elevated (30)High (50+)
Cost per patient outlier+3
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+51%
Cost per patient vs peers
$5,926 vs $3,933 avg
+21%
Brand preference vs peers
61.7% vs 51.2% avg
Brand vs Generic
38% generic
Brand: 4,896 claims · $6.3M
Generic: 3,041 claims · $82K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Semaglutide | 866 | $1.5M |
| Finerenone | 425 | $573K |
| Semaglutide | 260 | $451K |
| Empagliflozin | 320 | $433K |
| Insulin Aspart | 286 | $376K |
| Dulaglutide | 188 | $318K |
| Tirzepatide | 170 | $245K |
| Insulin Degludec | 122 | $234K |
| Insulin Degludec | 182 | $179K |
| Insulin Glargine,hum.Rec.Anlog | 210 | $162K |
| Insulin Glargine,hum.Rec.Anlog | 132 | $160K |
| Insulin Lispro | 108 | $143K |
| Insulin Regular, Human | 56 | $141K |
| Insulin Aspart | 71 | $131K |
| Insulin Regular, Human | 15 | $112K |
Prescribing Profile
Patient Profile
70
Avg Age
61%
Female
1.80
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About